Carbon-based light addressable potential aptasensor based on the synergy of C-MXene@rGO and OPD@NGQDs for low-density lipoprotein detection
- PMID: 39729216
- DOI: 10.1007/s00604-024-06909-w
Carbon-based light addressable potential aptasensor based on the synergy of C-MXene@rGO and OPD@NGQDs for low-density lipoprotein detection
Abstract
A novel carbon-based light-addressable potentiometric aptasensor (C-LAPS) was constructed for detection low-density lipoprotein (LDL) in serum. Carboxylated Ti3C2 MXene @reduced graphene oxide (C-MXene@rGO) was used as interface and o-phenylenediamine functionalized nitrogen-doped graphene quantum dots (OPD@NGQDs) as the photoelectric conversion element. The photosensitive layers composed of OPD@NGQDs/C-MXene@rGO exhibit superior photoelectric conversion efficiency and excellent biocompatibility, which contribute to an improved response signal. When LDL reacts with the LDL aptamer (LDLApt) immobilized on the photosensitive layers to form LDL-LDLApt complexes, the reaction process can induce the modification of the surface potential in the photosensitive layer, leading to potential shift observed through the I-V curves. The experimental conditions were successfully optimized with few planned tests by applying the Box-Behnken design and response surface methodology aspects of the Design-Expert software. Under the optimal condition, the potential shift had a linear relationship with concentrations of LDL from 0.02 to 0.30 μg/mL. The limit of detection (LOD) was 5.88 ng/mL (S/N = 3) and the sensitivity was 315.20 mV/μg·mL-1. In addition, the LDL C-LAPS demonstrated excellent specificity, reproducibility, and stability in detecting LDL. The sensor performed well in quantifying LDL in real samples. Therefore, the LDL C-LAPS has the potential for clinical applications.
Keywords: Box-Behnken design; C-LAPS; C-MXene@rGO; LDL; OPD@NGQDs.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.
Conflict of interest statement
Declarations. Ethical approval: The human serum samples used in this study were approved by the Ethics Committee of the 924th Hospital of Chinese People’s Liberation Army Joint Logistic Support Force in Guilin, China. Conflict of interest: The authors declare no competing interests.
References
-
- Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP (2019) Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD. J Am Coll Cardiol 76(2020):2982–3021. https://doi.org/10.1016/j.jacc.2020.11.010 - DOI
-
- Zhou YX, Wei J, Deng G, Hu A, Sun PY, Zhao XL, Song BL, Luo J (2023) Delivery of low-density lipoprotein from endocytic carriers to mitochondria supports steroidogenesis. Nat Cell Biol 25:937–949. https://doi.org/10.1038/s41556-023-01160-6 - DOI - PubMed
-
- Jiang H, Zhou YW, Nabavi SM, Sahebkar A, Little PJ, Xu S, Weng JP, Ge JJ (2022) Mechanisms of oxidized LDL-mediated endothelial dysfunction and its consequences for the development of atherosclerosis. Frontiers in Cardiovascular Medicine 9:925923. https://doi.org/10.3389/FCVM.2022.925923 - DOI - PubMed - PMC
-
- Zheng R, Lind L (2024) A combined observational and mendelian randomization investigation reveals nmr-measured analytes to be risk factors of major cardiovascular diseases. Sci Rep 14:10645. https://doi.org/10.1038/s41598-024-61440-5 - DOI - PubMed - PMC
-
- Boren J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, Daemen MJ, Demer LL, Hegele RA, Nicholls SJ (2020) Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the european atherosclerosis society consensus panel. Eur Heart J 41:2313–2330. https://doi.org/10.1093/eurheartj/ehz962 - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources